15-Dec-2011 - Evolva SA

Evolva obtains patent coverage in Russia on EV-077 for use in complications of diabetes

Evolva Holding SA announced that the Russian Patent Office has granted patent protection for EV-077 in the treatment of complications of diabetes for a term extending to 2026. This is the first patent granted covering EV-077. EV-077 patent applications are currently pending in Australia, Brazil, Canada, China, Europe, Hong Kong, India, Japan, Mexico and the USA. Evolva has filed related applications with the aim to extend the protection for its EV-077 portfolio to 2031 and beyond.

EV-077 prevents isoprostanes and prostanoids, levels of which are elevated in diabetics, from causing inflammatory damage to the vasculature. EV-077 is an oral small molecule  that belongs to a new structural class. The mechanism of action of EV-077 means that it can potentially ameliorate or prevent a range of diabetic complications (including loss of kidney function and increased risk of thrombosis). Evolva has recently received clearance to move EV-077 into Phase IIa in this indication. First data are expected by mid-2012.

Facts, background information, dossiers
More about Evolva
  • News

    Evolva announces new CEO

    Evolva announces that as part of entering the next phase of its evolution, the current Evolva CEO Simon Waddington steps down as CEO with immediate effect. Until he will leave the company towards the end of 2018, he will support the new CEO in completing work on Evolva’s technology base. Th ... more

    Neil Goldsmith stepping down as CEO and Board member of Evolva

    Evolva announces the departure of CEO Neil Goldsmith and his succession by the current Chief Operating Officer (COO), Simon Waddington. Since co-founding Evolva, Neil Goldsmith has been instrumental in Evolva’s development over the last thirteen years, moving the company from a pharmaceutic ... more

    Scott Fabro to Join Evolva as Chief Commercial Officer

    Evolva announces that Scott Fabro will join Evolva early July and shortly thereafter take over as Chief Commercial Officer, succeeding Luc Gruner. Scott has broad executive experience in various marketing functions in the food industry including ACH Foods, Kerry and Cargill. Most recently h ... more

  • Videos

    Eve explains Evolva's fermentation

    Evolva is a pioneer and global leader in sustainable, fermentation-based approaches to ingredients for health, wellness and nutrition. Evolva’s products include stevia, vanilla, saffron and resveratrol. As well as developing its own proprietary ingredients, Evolva also deploys its technolog ... more

  • Companies

    Evolva SA

    Evolva’s mission is to discover and provide innovative, sustainable ingredients for health, nutrition and wellness. Evolva uses biosynthetic and evolutionary technologies to create and optimise small molecule compounds and their production routes. We are active in consumer healthcare and nu ... more